There have been reports of noninfectious pneumonitis (including some with pulmonary hypertension as a secondary event), infections, and renal failure (including acute renal failure) in patients...
When It Comes to Patient Support—We’ve Got It Covered from the very beginning
Help start patients off on the right track. The programs can help counsel patients, secure alternative funding, answer insurance questions, and connect patients with free medication trials. The We’ve Got It Covered Program has what patients need to help navigate the treatment journey.
Patients receive a free 14-day supply of AFINITOR® (everolimus) Tablets at treatment initiation, allowing them to get on therapy promptly. Enrollment is easy—download the form at www.hcp.novartis.com/access.
Novartis Oncology shares your commitment to helping patients receive the medicines they need. Patient Assistance Now Oncology (PANO) provides access to information and our wide range of resources available to your patients in over 160 languages.
Support for patients includes:
To learn more, call 1-800-282-7630.
Patients may be eligible for immediate co-pay savings on their next prescription:
Limitations apply. Offer is not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice.
Encourage your patients to find out if they are eligible to enroll in the Universal Co-pay Program by visiting www.CoPay.NovartisOncology.com or calling 1-877-577-7756.
Terms and Conditions
This offer is valid only for those with commercial insurance. Offer not valid under Medicare, Medicaid, or any other federal or state program. Not valid for cash-paying patients, where product is not covered by patient’s commercial insurance, or where plan reimburses you for entire cost of your prescription drug. Offer is not valid where prohibited by law. Valid only in the United States and Puerto Rico. This program is not health insurance. Offer may not be combined with any other rebate, coupon, or offer. The card is the property of Novartis Pharmaceuticals Corporation and must be returned upon request. Novartis reserves the right to rescind, revoke, or amend the program without notice. Patient certifies responsibility for complying with applicable limitations, if any, of any commercial insurance and reporting receipt of program rewards, if necessary, to any commercial insurer. This offer expires on December 31, 2018.
Finding a pharmacy
|If a patient's plan requires a specific pharmacy to fill an AFINITOR prescription, simply call 1-877-433-8067 to reach our dedicated We've Got It Covered patient support counselors for help.|
Information for Day-to-Day Patient Support Resources
The Novartis Oncology Day-to-Day Patient Support Resources give patients information about a range of independent support organizations that can provide services to complement their treatment plan and care.
|Transportation and lodging services
Organizations that can help patients access free or reduced air, lodging, and ground transportation services so that they can attend their medical appointments.
Preparing healthy meals
Mind and body
All organizations listed are not-for-profit and/or government agencies, and are independent from Novartis Pharmaceuticals Corporation. Novartis has no financial interest in any organization listed, but may provide occasional funding support to these organizations. All descriptions are copyright of the respective organizations.
Patient Counseling Kit
The kit includes a patient education brochure, nonprescription products, and resources patients can use while on therapy.
This website is a convenient one-stop resource for a variety of education and counseling materials for you and your patients, including coverage, financial assistance, education, patient support, and adverse reaction resources.
This is a website specifically designed for office reimbursement staff to help them understand plan-specific coverage criteria and gain access to prior authorization forms, AFINITOR counseling resources, and educational materials.
AFINITOR is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane after failure of treatment with letrozole or anastrozole.
Important Safety Information
AFINITOR is contraindicated in patients with hypersensitivity to everolimus, to other rapamycin derivatives, or to any of the excipients.
Angioedema With Concomitant Use of Angiotensin-Converting Enzyme (ACE) Inhibitors
Impaired Wound Healing
Laboratory Tests and Monitoring
Please see full Prescribing Information.